Pazopanib Maintenance for SCLC

Phase 2

Completed

• Conditions: SCLC
• Interventions: Drug: Pazopanib; Drug: Placebo

• Registration Number: NCT01797874
• Lead Sponsor: Samsung Medical Center

Brief Summary

To evaluate the efficacy of pazopanib maintenance after 1st line CTx for SCLC.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2013-02-21
• Study First Submitted QC: 2013-02-22
• Study First Posted: 2013-02-25
• Study Start: 2013-06
• Primary Completion: 2017-02
• Study Completion: 2017-12
• Status Verified: 2019-12
• Last Update Submitted: 2019-12-05
• Last Update Posted: 2019-12-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 97

Inclusion Criteria

• histologically confirmed SCLC
• no disease progression after 4 cycles of etoposide/platinum 1st-line therapy
• history of 4 cycles of etoposide/platinum 1st-line therapy
• between 21 days and 42 days since C4D1 of etoposide/platinum
• no symptomatic brain meta

Exclusion Criteria

• poor hepatic, renal function

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Pazopanib	Pazopanib	pazopanib maintenance after 4 cycles of etoposide/platinum in SCLC
placebo	Placebo	placebo after 4 cycles of etoposide/platinum chemotherapy in SCLC

Primary Outcome Measures

Name	Time	Method
Progression-free survival	12 months

Trial Locations

Locations (1)

Samsung Medical Center; 🇰🇷 Seoul, Korea, Republic of